Multi-Drug Resistant Clinical Pseudomonas Aeruginosas Inhibited by Ferula Gummosa Boiss Publisher Pubmed



Satarian F¹ ; Hosseini HM¹ ; Ghadaksaz A¹ ; Amin M² ; Fooladi AAI¹
Source: Recent Patents on Anti-Infective Drug Discovery Published:2018

Abstract

Background: Multi-drug resistance among Pseudomonas aeruginosa (P. aeruginosa) clinical isolates is increasing and becoming a serious problem for public health authorities worldwide. Objective: The aim of the current study is to introduce a potent antibacterial compound against the resistant P. aeruginosa. Methods: In this study, we evaluated the antibacterial effects of extracts and essential oils of Ferula gummosa Boiss (F. gummosa) on 33 P. aeruginosa clinical isolates by microdilu-tion method and assessed the association of antimicrobial activity with the extended spectrum β-lactamase (ESBL) producing, biofilm forming and aliginate production of the strains. In addition, the presence of some genes involved in these properties, including blaG-ES-1, blaRER-1, blaCTX-M, blaVEB-1, blaOXA-1, blaOXA-4, blaOXA-10, ppyR, pslA, pelA, algU, algL, algD, fliC and oxaA was determined using PCR. Results: We revealed that all of our extracts and essential oils had significant antibacterial effects (p<0.001), but the aqueous extracts showed a relatively lower antibacterial activity compared with the methanolic ones. Furthermore, the minimum inhibitory concentration required for the ESBL producing strains was significantly higher than the non-ESBL producing ones (p<0.001). Loss of some genes such as blaPER-1, blaGES-1, blaOXA-1 and blaOXA-4 caused sensitivity to F. gummosa derivatives (p<0.05). Conclusion: The findings of this study indicate that the antibacterial effects of the extract and essential oils of F. gummosa may be a potential novel treatment against drug-resistant P. aeruginosa clinical isolates. © 2018 Bentham Science Publishers.